Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FDA To Rescind A 510(k): Rare Action Targets ReGen's Menaflex Device

This article was originally published in The Pink Sheet Daily

Executive Summary

The formal rescission process, including the option for ReGen to request a regulatory hearing, will proceed after FDA staffers have met with the manufacturer to discuss an appropriate marketing pathway for the device.

You may also be interested in...

With Panel Advice In, FDA To Conclude Menaflex 510(k) Re-Review In Weeks

FDA will announce the outcome of its re-review of ReGen Biologic's 510(k)-cleared Menaflex knee repair device "in the coming weeks," CDRH Director Jeffrey Shuren said last week

Internal FDA Menaflex Investigation Finds Serious Process Deviations

An internal evaluation of FDA's handling of the controversial 510(k) clearance of a knee implant unearthed serious shortcomings in the integrity of the agency's review process, FDA said Sept. 24

Device Center Discord: 510(k) Review Process Is Flash Point At CDRH

Details trickling into the public sphere about CDRH's device review process reveal heightened tension between reviewers and management over the proper response to a 510(k) submission





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts